Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTAZ05C)

• DTT Name: RAC-gamma serine/threonine-protein kinase (AKT3) DTT Info
• Gene Name: AKT3

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[1]

11 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[2]
GSK2141795	DMSHE70	Colorectal cancer	2B91.Z	Phase 2	[3]
MK-2206	DMT1OZ6	Rectal adenocarcinoma	2B92	Phase 2	[4]
BAY1125976	DMTB4R8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
GSK690693	DMRBVHE	Haematological malignancy	2B33.Y	Phase 1	[5]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
SR13668	DMO5760	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
TCN-P	DMV0AH8	Acute myeloid leukaemia	2A60	Phase 1	[10]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Akt inhibitor VIII	DMDVIT1	Discovery agent	N.A.	Investigative	[12]
ISC-4	DMH6YVD	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[14]

References

• [1] The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
• [4] First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
• [5] Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74.
• [6] A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
• [7] DOI: 10.1016/S1359-6349(10)71767-5
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
• [10] Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.
• [11] Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
• [12] Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2286).
• [14] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.